These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 21708108

  • 1. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
    Birninger N, Bornhäuser M, Schaich M, Ehninger G, Schetelig J.
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
    [Abstract] [Full Text] [Related]

  • 2. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [Abstract] [Full Text] [Related]

  • 3. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY, Ren HY, Qiu ZX, Wang Y, Cen XN, Wang LH, Wang MJ, Xu WL, Wang WS, Li Y, Dong YJ, Ou JP, Liang ZY, Liu W, Wang Q.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [Abstract] [Full Text] [Related]

  • 4. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
    Kataoka K, Nannya Y, Ueda K, Kumano K, Takahashi T, Kurokawa M.
    Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

  • 6. Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).
    Patel P, Sweiss K, Nimmagadda S, Gao W, Rondelli D.
    Bone Marrow Transplant; 2011 Oct; 46(10):1326-30. PubMed ID: 21132027
    [Abstract] [Full Text] [Related]

  • 7. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
    Lim ZY, Ingram W, Brand R, Ho A, Kenyon M, Devereux S, Marsh J, Mufti GJ, Pagliuca A.
    Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
    [Abstract] [Full Text] [Related]

  • 8. Favorable outcomes after allogeneic hematopoietic stem cell transplantation in children with high-risk or advanced acute myeloid leukemia.
    Koh KN, Park M, Kim BE, Bae KW, Im HJ, Seo JJ.
    J Pediatr Hematol Oncol; 2011 May; 33(4):281-8. PubMed ID: 21464766
    [Abstract] [Full Text] [Related]

  • 9. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D, Martino R, Sureda A, Canals C, Altés A, Briones J, Sanz MA, Parody R, Constans M, Villela SL, Brunet S, Sierra J.
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.
    Guilfoyle R, Demers A, Bredeson C, Richardson E, Rubinger M, Szwajcer D, Seftel MD.
    Bone Marrow Transplant; 2009 Jan; 43(2):133-9. PubMed ID: 18762762
    [Abstract] [Full Text] [Related]

  • 12. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
    Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C, Russell NH.
    Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
    [Abstract] [Full Text] [Related]

  • 13. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P.
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [Abstract] [Full Text] [Related]

  • 14. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
    Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, Fujisawa S, Sakamaki H, Aotsuka N, Yokota A, Kanda Y, Sakura T, Nanya Y, Saitoh T, Kanamori H, Takahashi S, Okamoto S.
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
    [Abstract] [Full Text] [Related]

  • 15. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.
    Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K, Hartmann F, Horst HA, Koller E, Petzer A, Grimminger W, Kobbe G, Glasmacher A, Salwender H, Kirchen H, Haase D, Kremers S, Matzdorff A, Benner A, Döhner H.
    J Clin Oncol; 2010 Oct 20; 28(30):4642-8. PubMed ID: 20805454
    [Abstract] [Full Text] [Related]

  • 16. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ.
    Biol Blood Marrow Transplant; 2007 Apr 20; 13(4):486-92. PubMed ID: 17382255
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan 20; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 18. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF.
    Biol Blood Marrow Transplant; 2008 Feb 20; 14(2):181-6. PubMed ID: 18215778
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D, Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Haematologica; 2006 Apr 20; 91(4):513-21. PubMed ID: 16533723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.